Recent Posts
- HealthInvest June 2026: A Look Inside Australia's Healthcare Innovations16 Jun 2026
- HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences19 May 2026
- Lifesaving Capital: How impact investing is shaping the future of biotech30 Apr 2026
- Investor Relations: the quiet advantage powering ASX microcaps28 Nov 2025
- HealthInvest Sydney: Life Sciences in the Investor Spotlight06 Oct 2025
Archives
Atomo Diagnostics (ASX: AT1) presents at IRD Invest

John Kelly, Founder, Managing Director & CEO and Will Souter, Chief Financial Officer, Atomo Diagnostics (ASX: AT1)
Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers.
Atomo has supply agreements in place for tests targeting infectious diseases including HIV, COVID-19, and viral vs bacterial differentiation.
Watch John Kelly and Will Souter's IRD Invest presentation in the window below.

